28355968|t|Abiraterone - induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature
28355968|a|Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
28355968	0	11	Abiraterone	T109,T121	C0754011
28355968	14	21	induced	T169	C0458082
28355968	22	36	rhabdomyolysis	T046	C0035410
28355968	50	69	acute kidney injury	T037	C2609414
28355968	73	84	case report	T170	C0007320
28355968	89	113	review of the literature	T170	C0282441
28355968	114	125	Abiraterone	T109,T121	C0754011
28355968	129	144	CYP17 inhibitor	T121	C3160096
28355968	153	174	androgen biosynthesis	T044	C1157302
28355968	187	193	tissue	T024	C0040300
28355968	221	231	prednisone	T109,T121,T125	C0032952
28355968	253	273	first-line treatment	T061	C1708063
28355968	278	288	metastatic	T191	C2939420
28355968	289	325	castration-resistant prostate cancer	T191	C1328504
28355968	340	344	case	T077	C1706256
28355968	348	362	rhabdomyolysis	T046	C0035410
28355968	379	390	abiraterone	T109,T121	C0754011
28355968	391	398	therapy	T061	C0087111
28355968	412	417	acute	T037	C2609414
28355968	421	428	chronic	T079	C0205191
28355968	429	442	kidney injury	T037	C0160420
28355968	448	455	patient	T101	C0030705
28355968	461	471	metastatic	T191	C2939420
28355968	472	508	castration-resistant prostate cancer	T191	C1328504
28355968	517	527	monitoring	T062	C1516647
28355968	550	558	patients	T101	C0030705
28355968	570	581	abiraterone	T109,T121	C0754011
28355968	602	614	risk factors	T033	C0035648
28355968	630	644	rhabdomyolysis	T046	C0035410